{"id":571228,"date":"2021-10-26T22:30:02","date_gmt":"2021-10-26T22:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=571228"},"modified":"2021-10-26T22:30:02","modified_gmt":"2021-10-26T22:30:02","slug":"triplenegative-breast-cancer-clinical-nonclinical-trials-analysis-emerging-pipeline-therapies-and-treatment-algorithm-key-companies-cytodyn-hibercell-roche-infinity-pharma-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/triplenegative-breast-cancer-clinical-nonclinical-trials-analysis-emerging-pipeline-therapies-and-treatment-algorithm-key-companies-cytodyn-hibercell-roche-infinity-pharma-and-others_571228.html","title":{"rendered":"Triple-Negative Breast Cancer Clinical &#038; Non-Clinical Trials Analysis, Emerging Pipeline Therapies, and Treatment Algorithm | Key Companies &#8211; CytoDyn, HiberCell, Roche, Infinity Pharma, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Triple-Negative Breast Cancer Clinical &amp; Non-Clinical Trials Analysis, Emerging Pipeline Therapies, and Treatment Algorithm | Key Companies - CytoDyn, HiberCell, Roche, Infinity Pharma, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Triple-Negative Breast Cancer Clinical &amp; Non-Clinical Trials Analysis, Emerging Pipeline Therapies, and Treatment Algorithm | Key Companies - CytoDyn, HiberCell, Roche, Infinity Pharma, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Triple-Negative Breast Cancer Pipeline Insight, 2021&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Triple-Negative Breast Cancer Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Triple-Negative Breast Cancer Pipeline<\/strong> report embraces in-depth commercial and clinical assessment of the Triple-Negative Breast Cancer pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, <strong>Triple-Negative Breast Cancer collaborations<\/strong>, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Triple-Negative Breast Cancer Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/03c0a9fc8e7dbebef82f4f5fb7cf3ebf.jpg\" alt=\"Triple-Negative Breast Cancer Pipeline Analysis\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Triple-Negative Breast Cancer Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing <strong>therapies for the treatment of Triple-Negative Breast Cancer<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Triple-Negative Breast Cancer Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Triple-Negative Breast Cancer key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Triple-Negative Breast Cancer Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Triple-Negative Breast Cancer market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Triple-Negative Breast Cancer Therapeutics Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Triple-Negative Breast Cancer (TNBC) Companies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">HiberCell<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Hoffmann-La Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Infinity Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Treadwell Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CytoDyn<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Triple-Negative Breast Cancer (TNBC) therapies covered in the report include&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Imprime PGG<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ipatasertib<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">IPI-549 (eganelisib)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leronlimab (PRO 140)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CFI-400945<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample Pages @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Triple-Negative Breast Cancer Emerging Therapies and Key Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">A better understanding of disease pathogenesis contributing to the development of <strong>novel therapeutics for Triple-Negative Breast Cancer<\/strong>.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the coming years, the <strong>Triple-Negative Breast Cancer market<\/strong> is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The companies and academics are working to assess challenges and seek opportunities that could influence <strong>Triple-Negative Breast Cancer Research &amp; Development<\/strong>. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">A detailed portfolio of major pharma players who are involved in fueling the Triple-Negative Breast Cancer treatment market. Several potential<strong> therapies for Triple-Negative Breast Cancer<\/strong> are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Triple-Negative Breast Cancer market size in the coming years.&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Our in-depth analysis of the <strong>Triple-Negative Breast Cancer pipeline assets<\/strong> (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download Sample Pages @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Triple-Negative Breast Cancer Therapeutics Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Triple-Negative Breast Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Triple-Negative Breast Cancer Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Triple-Negative Breast Cancer &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Triple-Negative Breast Cancer Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Triple-Negative Breast Cancer Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Triple-Negative Breast Cancer Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Triple-Negative Breast Cancer Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Triple-Negative Breast Cancer Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Triple-Negative Breast Cancer Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Triple-Negative Breast Cancer Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Triple-Negative Breast Cancer Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Triple-Negative Breast Cancer Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Visit to get the sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/triple-negative-breast-cancer-tnbc-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=triplenegative-breast-cancer-clinical-nonclinical-trials-analysis-emerging-pipeline-therapies-and-treatment-algorithm-key-companies-cytodyn-hibercell-roche-infinity-pharma-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=triplenegative-breast-cancer-clinical-nonclinical-trials-analysis-emerging-pipeline-therapies-and-treatment-algorithm-key-companies-cytodyn-hibercell-roche-infinity-pharma-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP Triple-Negative Breast Cancer Pipeline Insight, 2021&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Triple-Negative Breast Cancer Market. The Triple-Negative Breast Cancer Pipeline report embraces in-depth commercial and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/triplenegative-breast-cancer-clinical-nonclinical-trials-analysis-emerging-pipeline-therapies-and-treatment-algorithm-key-companies-cytodyn-hibercell-roche-infinity-pharma-and-others_571228.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-571228","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/571228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=571228"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/571228\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=571228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=571228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=571228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}